Pittenger & Anderson Inc. Sells 1,574 Shares of Medpace Holdings, Inc. $MEDP

Posted by George Bondi on Jul 13th, 2026

Pittenger & Anderson Inc. decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 88.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 202 shares of the company’s stock after selling 1,574 shares during the quarter. Pittenger & Anderson Inc.’s holdings in Medpace were worth $97,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of MEDP. BOKF NA boosted its holdings in Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after acquiring an additional 20 shares during the last quarter. Valeo Financial Advisors LLC raised its holdings in Medpace by 5.0% during the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after purchasing an additional 21 shares during the last quarter. UMB Bank n.a. raised its holdings in Medpace by 5.6% during the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after purchasing an additional 24 shares during the last quarter. Schulhoff & Co. Inc. lifted its position in Medpace by 1.1% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after purchasing an additional 25 shares during the period. Finally, Kaufman Rossin Wealth LLC lifted its position in Medpace by 3.4% during the 4th quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock valued at $447,000 after purchasing an additional 26 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Performance

MEDP opened at $538.23 on Monday. The firm’s fifty day moving average is $467.24 and its two-hundred day moving average is $495.50. The firm has a market cap of $15.37 billion, a PE ratio of 33.83, a price-to-earnings-growth ratio of 2.73 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $306.70 and a twelve month high of $628.92.

Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. During the same quarter in the previous year, the business earned $3.67 EPS. The firm’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insider Transactions at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.50% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Royal Bank Of Canada reduced their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. BMO Capital Markets dropped their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Finally, Barclays cut their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Two research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $469.17.

View Our Latest Stock Analysis on Medpace

Medpace Profile

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.